Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor
This article was originally published in The Tan Sheet
Executive Summary
A 1,200-subject actual use trial to simulate the OTC use of Lipitor 10 mg did not meet its primary objectives of demonstrating patient compliance with the direction to check low-density lipoprotein cholesterol level and after checking their LDL-C level take appropriate action based on test results.
You may also be interested in...
VeriSIM Expects AI Use To Trim Margin For Failure In OTC Switches, Help Boost Revenue Margins
“It's a very expensive process for an OTC drug because you don't make significantly high margins compared to a blockbuster cancer drug. For pharma companies utilizing our platform, you can reduce that efficiency challenge and increase the probability of success,” says VeriSIM CEO Jo Varshney.
Little Innovation In US OTC Switches For 20 Years, ACNU Won't Remove Impediments – Study
Of 45 switches since 2002, three added an indication to OTC market and three were “an exceptional innovation” offering “a genuinely novel OTC product, providing a new to OTC active pharmaceutical ingredient, pharmacological class, and indication,” Haleon researchers found.
Naloxone OTC Switch NDA Has US FDA Concerned Labeling Will Cause User Error, Delay Delivery
CDER will ask advisory panel “whether additional labeling information might mitigate risk of use errors” for Emergent’s naloxone nasal spray made available OTC and whether results of firm’s human factors study “support that consumers are able to correctly administer nonprescription [naloxone nasal spray] in an emergency situation.”